CytomX Therapeutics Inc
$ 4.39
-0.23%
26 Dec - close price
- Market Cap 743,821,000 USD
- Current Price $ 4.39
- High / Low $ 4.48 / 4.26
- Stock P/E 14.63
- Book Value 0.65
- EPS 0.30
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.10 %
- ROE 0.67 %
- 52 Week High 4.62
- 52 Week Low 0.40
About
CytomX Therapeutics, Inc. is a pioneering biopharmaceutical company based in South San Francisco, California, specializing in innovative cancer therapies through its proprietary Probody™ technology platform. This unique approach facilitates the development of highly selective treatments designed to minimize off-tumor effects while maximizing anti-tumor effectiveness, addressing critical unmet needs in oncology. With a diverse pipeline of candidates at varying clinical stages and a commitment to strategic partnerships, CytomX is well-positioned to enhance patient outcomes and set new standards in cancer treatment. The company's focus on improving therapeutic precision underscores its role as a leader in the evolving biopharmaceutical landscape.
Analyst Target Price
$7.07
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-06 | 2025-03-10 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-03-11 | 2023-11-07 | 2023-08-08 | 2023-05-09 | 2023-03-27 |
| Reported EPS | -0.09 | -0.0012 | 0.27 | 0.23 | 0.07 | -0.08 | 0.17 | 0.01 | 0.04 | -0.02 | -0.05 | -0.43 |
| Estimated EPS | -0.05 | -0.06 | 0.1322 | -0.1059 | -0.17 | -0.14 | -0.08 | -0.03 | -0.19 | -0.2 | -0.11 | -0.24 |
| Surprise | -0.04 | 0.0588 | 0.1378 | 0.3359 | 0.24 | 0.06 | 0.25 | 0.04 | 0.23 | 0.18 | 0.06 | -0.19 |
| Surprise Percentage | -80% | 98% | 104.236% | 317.186% | 141.1765% | 42.8571% | 312.5% | 133.3333% | 121.0526% | 90% | 54.5455% | -79.1667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.0924 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CTMX
2025-12-26 20:09:14
CytomX Therapeutics, Inc. (NASDAQ:CTMX) has received a "Moderate Buy" consensus rating from seven analysts, with six recommending "Buy" and one "Hold." The average 12-month price target is $6.67, with some firms raising targets while Wall Street Zen downgraded the stock to "Sell." The clinical-stage biopharmaceutical company missed Q3 earnings and revenue expectations but institutional investors have shown increased interest, with the stock currently trading around $4.44.
2025-12-26 13:09:17
Precision Wealth Strategies LLC acquired 237,081 shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) during Q3, valued at approximately $756,000, giving them a 0.14% stake in the company. CytomX Therapeutics missed Q3 earnings expectations, reporting an EPS of ($0.09) against a consensus of ($0.04) and revenue of $5.96 million against an $11.50 million estimate. Despite the missed earnings, analysts maintain a "Moderate Buy" rating for CTMX with a consensus target price of $6.67.
2025-12-26 11:09:17
Inspire Investing LLC has acquired a new position of 522,482 shares in CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the third quarter, valued at approximately $1.67 million. This acquisition, along with significant stakes bought by other institutional investors like OrbiMed and Perceptive Advisors, highlights growing institutional interest in the biotechnology company. Analysts have a "Moderate Buy" consensus rating for CTMX with a target price of $6.67, despite the company recently missing its quarterly EPS estimate.
2025-12-21 13:09:25
Analyst sentiment is bullish on CytomX Therapeutics (CTMX) as 90% of analysts rate it a "Buy" with a median price target of $6.50, suggesting a 58.20% upside. H.C. Wainwright reiterated a "Buy" rating and a $10.00 price target ahead of crucial data for the company's CX-2051 therapy for colorectal cancer. The investment firm outlined various scenarios for the treatment's performance, supported by promising interim results and progress in its clinical trials.
2025-12-19 21:09:21
CytomX Therapeutics' stock has delivered a 256% return to shareholders over the last year, significantly outperforming its 44% earnings per share growth. This suggests increased market optimism for the company. Despite recent short-term fluctuations, the long-term trend appears positive, although previous five-year returns show an annual loss.
2025-12-19 12:08:27
CytomX Therapeutics (NASDAQ: CTMX) shareholders have seen a significant 256% return over the last year, outperforming the company's 44% earnings per share growth. This suggests increased market optimism for the stock, despite a longer-term five-year annualized loss of 8%. Investors are encouraged to look beyond short-term fluctuations and assess underlying fundamentals and potential warning signs.
